Positive Trends in Biomanufacturing Budgets: Biopharma and Vendor Budgets Are Up For the First Time in Three Years

by Eric S. Langer
Volume 10, Issue 1 (Summer 2011)

While global economies continue to struggle back from the recent recession, we are seeing clear evidence that budgets in most areas of biopharmaceutical manufacturing are returning to pre-crisis conditions. Because of the essential nature of pharmaceutical products and health services, healthcare sectors tend to be more recession resistant and return to growth sooner than other industries. In fact, respondents to our 8th Annual Report and Survey of Biopharmaceutical Manufacturing projected only increases for all budget areas this year. This is a change from last year where budgets continued to show decreases in areas ranging from outsourcing production, hiring new scientific staff, and new facility construction. As the financing crunch lightens, biomanufacturing facilities are reopening their wallets. However, anecdotally, vendors to the industry are indicating that buyers are continuing to be much more cautious with their spending. Sales cycles continue to be drawn out, and many end users are demanding more milestone performance and risk sharing from suppliers...

Citation:
Langer ES. Positive Trends in Biomanufacturing Budgets: Biopharma and Vendor Budgets Are Up For the First Time in Three Years. BioProcess J, 2011; 10(1): 28-32. http://dx.doi.org/10.12665/J101.Langer.